

News Release

No.24002
March 22, 2024
Noile-Immune Biotech, Inc.
<https://www.noile-immune.com>

**Presentation at the 23rd Congress of the Japanese Society for Regenerative Medicine
Challenge for Manufacturing Gene-modified T cells using an Automated Culture System**

Noile-Immune Biotech, Inc. (2-12-10 Shiba-Daimon, Minato-ku, Tokyo, President & CEO: Koji Tamada, hereinafter "Noile-Immune") announces that Dr. Yukimi Sakoda, Associate Professor, Yamaguchi University Graduate School of Medicine, and a research partner of Noile-Immune, presented the progress of collaborative project, entitled "Challenge for manufacturing gene-modified T cells using an automated culture system", in a seminar co-hosted by Shibuya Corporation, at the 23rd Congress of the Japanese Society for Regenerative Medicine at TOKI MESSE Niigata Convention Center/Hotel Nikko Niigata from March 21st to 23rd, 2024.

Please note that Nikkei Biotech's coverage of this presentation has been published.

For more information, please see <https://bio.nikkeibp.co.jp/atcl/news/p1/24/03/22/11717/>.

Noile-Immune Biotech Inc., established as a university start-up, aims to contribute to the arrival of an era when we can overcome cancer through the next-generation cancer immunotherapies, centering on PRIME technology.

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech, Inc.

E-mail: pr@noile-immune.com